← Human Trials & Peer-Reviewed Studies
Add-On Bifidobacterium Bifidum Supplement in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Week Randomized Double-Blind Placebo-Controlled Clinical Trial.
Plain-language guide to PMID 39064703 (2024): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 39064703
- Journal
- Nutrients
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Wang LJ et al. (10 authors)
- DOI
- 10.3390/nu16142260
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
The researchers conducted a 12-week randomized double-blind placebo-controlled clinical trial to investigate the potential impact of Bifidobacterium bifidum (Bf-688) supplementation on attention-deficit/hyperactivity disorder (ADHD).
Why It Was Studied
All participants underwent assessments using Conners' Continuous Performance Test (CPT) and Conners' Continuous Auditory Test of Attention (CATA).
Additionally, fecal samples were collected at the beginning of the trial (week 0) and at the endpoint (week 12).
Who Took Part
PubMed indexes the participants as children, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
As a double-blind Copper (Supplement) study, the assignments were hidden from both participants and investigators until the end.
A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.
What Was Measured
All participants underwent assessments using Conners' Continuous Performance Test (CPT) and Conners' Continuous Auditory Test of Attention (CATA).
Additionally, fecal samples were collected at the beginning of the trial (week 0) and at the endpoint (week 12).
PubMed files the paper under topics including Attention, Attention Deficit Disorder with Hyperactivity, Bifidobacterium bifidum, Dietary Supplements, Feces, Gastrointestinal Microbiome and Methylphenidate.
Author keywords: ADHD, gut–brain axis, probiotic and psychobiotics.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The publication is from 2024 (Nutrients), a journal based in Switzerland.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.